Monopar Therapeutics MNPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$14.98M+9.6% | -$13.72M+12.0% | -$19.44M-200% | -$17.31M-143% | -$16.57M-118% | ||
| $5.18M+139% | $4.84M+324% | $4.01M+200% | $3.11M+93.1% | $2.17M+23.8% | ||
| -$10.01M+3.8% | -$12.2M-90.5% | -$10.83M-82.0% | -$9.81M-43.9% | -$10.41M-43.8% | ||
| -$68.71M-402% | -$63.45M-343% | -$15.6M-625% | -$12.49M-729% | -$13.68M-377% | ||
| $91.87M— | $91.96M— | $148.1M— | —— | —— | ||
| —— | —— | $121.66M— | $33.38M— | $31.9M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monopar Therapeutics generate?
- Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
- Where does Monopar Therapeutics's cash flow data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.